Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2025)
Historic Short term Debt for Rigel Pharmaceuticals (RIGL) over the last 3 years, with Q3 2025 value amounting to $29.8 million.
- Rigel Pharmaceuticals' Short term Debt changed N/A to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year change of. This contributed to the annual value of $7.3 million for FY2024, which is 59.48% up from last year.
- Latest data reveals that Rigel Pharmaceuticals reported Short term Debt of $29.8 million as of Q3 2025.
- In the past 5 years, Rigel Pharmaceuticals' Short term Debt registered a high of $29.8 million during Q3 2025, and its lowest value of $7.2 million during Q4 2023.
- In the last 3 years, Rigel Pharmaceuticals' Short term Debt had a median value of $14.8 million in 2024 and averaged $16.0 million.
- In the last 5 years, Rigel Pharmaceuticals' Short term Debt skyrocketed by 59.48% in 2024 and then rose by 23.68% in 2025.
- Over the past 3 years, Rigel Pharmaceuticals' Short term Debt (Quarter) stood at $7.2 million in 2023, then rose by 0.59% to $7.3 million in 2024, then skyrocketed by 309.25% to $29.8 million in 2025.
- Its Short term Debt stands at $29.8 million for Q3 2025, versus $22.4 million for Q2 2025 and $14.8 million for Q1 2025.